Extended-release naltrexone plus medical management alcohol treatment in primary care: Findings at 15 months

Joshua Lee, Ellie Grossman, Laura Huben, Marc Manseau, Jennifer McNeely, John Rotrosen, David Stevens, Marc Gourevitch

Research output: Contribution to journalArticle

Abstract

The feasibility of long-term extended-release naltrexone (XR-NTX) alcohol treatment is unknown. Following an initial 12-week, single-arm, observational trial of XR-NTX plus medical management (MM) in primary care, we offered 48 additional weeks of XR-NTX treatment (12 additional monthly injections) in two public primary care clinics as a naturalistic extension study. Of 65 alcohol dependent adults initiating XR-NTX treatment, 40 (62%) completed the initial 12-week XR-NTX observational trial, and 19 (29%) continued treatment for a median of 38. weeks total (range, 16-72. weeks; median 8 total XR-NTX injections). Among active extension phase participants, self-reported rates of drinking days (vs. last 30 days pre-treatment baseline) were low: median 0.2 vs. 6.0. drinks per day; 82 vs. 38% days abstinent; 11 vs. 61% heavy drinking days. Long-term XR-NTX treatment in a primary care MM model was feasible and may promote lasting drinking reductions or alcohol abstinence (clinical trial: NCT00620750).

Original languageEnglish (US)
Pages (from-to)458-462
Number of pages5
JournalJournal of Substance Abuse Treatment
Volume43
Issue number4
DOIs
StatePublished - Dec 2012

Fingerprint

Naltrexone
Primary Health Care
Alcohols
Drinking
Therapeutics
Alcohol Abstinence
Injections
Clinical Trials

Keywords

  • Alcohol medical management
  • Alcohol pharmacotherapy
  • Alcohol treatment
  • Extended-release naltrexone
  • Primary care

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Phychiatric Mental Health
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Extended-release naltrexone plus medical management alcohol treatment in primary care : Findings at 15 months. / Lee, Joshua; Grossman, Ellie; Huben, Laura; Manseau, Marc; McNeely, Jennifer; Rotrosen, John; Stevens, David; Gourevitch, Marc.

In: Journal of Substance Abuse Treatment, Vol. 43, No. 4, 12.2012, p. 458-462.

Research output: Contribution to journalArticle

Lee, Joshua ; Grossman, Ellie ; Huben, Laura ; Manseau, Marc ; McNeely, Jennifer ; Rotrosen, John ; Stevens, David ; Gourevitch, Marc. / Extended-release naltrexone plus medical management alcohol treatment in primary care : Findings at 15 months. In: Journal of Substance Abuse Treatment. 2012 ; Vol. 43, No. 4. pp. 458-462.
@article{262306c0d45149749d0d4f04977886d8,
title = "Extended-release naltrexone plus medical management alcohol treatment in primary care: Findings at 15 months",
abstract = "The feasibility of long-term extended-release naltrexone (XR-NTX) alcohol treatment is unknown. Following an initial 12-week, single-arm, observational trial of XR-NTX plus medical management (MM) in primary care, we offered 48 additional weeks of XR-NTX treatment (12 additional monthly injections) in two public primary care clinics as a naturalistic extension study. Of 65 alcohol dependent adults initiating XR-NTX treatment, 40 (62{\%}) completed the initial 12-week XR-NTX observational trial, and 19 (29{\%}) continued treatment for a median of 38. weeks total (range, 16-72. weeks; median 8 total XR-NTX injections). Among active extension phase participants, self-reported rates of drinking days (vs. last 30 days pre-treatment baseline) were low: median 0.2 vs. 6.0. drinks per day; 82 vs. 38{\%} days abstinent; 11 vs. 61{\%} heavy drinking days. Long-term XR-NTX treatment in a primary care MM model was feasible and may promote lasting drinking reductions or alcohol abstinence (clinical trial: NCT00620750).",
keywords = "Alcohol medical management, Alcohol pharmacotherapy, Alcohol treatment, Extended-release naltrexone, Primary care",
author = "Joshua Lee and Ellie Grossman and Laura Huben and Marc Manseau and Jennifer McNeely and John Rotrosen and David Stevens and Marc Gourevitch",
year = "2012",
month = "12",
doi = "10.1016/j.jsat.2012.08.012",
language = "English (US)",
volume = "43",
pages = "458--462",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Extended-release naltrexone plus medical management alcohol treatment in primary care

T2 - Findings at 15 months

AU - Lee, Joshua

AU - Grossman, Ellie

AU - Huben, Laura

AU - Manseau, Marc

AU - McNeely, Jennifer

AU - Rotrosen, John

AU - Stevens, David

AU - Gourevitch, Marc

PY - 2012/12

Y1 - 2012/12

N2 - The feasibility of long-term extended-release naltrexone (XR-NTX) alcohol treatment is unknown. Following an initial 12-week, single-arm, observational trial of XR-NTX plus medical management (MM) in primary care, we offered 48 additional weeks of XR-NTX treatment (12 additional monthly injections) in two public primary care clinics as a naturalistic extension study. Of 65 alcohol dependent adults initiating XR-NTX treatment, 40 (62%) completed the initial 12-week XR-NTX observational trial, and 19 (29%) continued treatment for a median of 38. weeks total (range, 16-72. weeks; median 8 total XR-NTX injections). Among active extension phase participants, self-reported rates of drinking days (vs. last 30 days pre-treatment baseline) were low: median 0.2 vs. 6.0. drinks per day; 82 vs. 38% days abstinent; 11 vs. 61% heavy drinking days. Long-term XR-NTX treatment in a primary care MM model was feasible and may promote lasting drinking reductions or alcohol abstinence (clinical trial: NCT00620750).

AB - The feasibility of long-term extended-release naltrexone (XR-NTX) alcohol treatment is unknown. Following an initial 12-week, single-arm, observational trial of XR-NTX plus medical management (MM) in primary care, we offered 48 additional weeks of XR-NTX treatment (12 additional monthly injections) in two public primary care clinics as a naturalistic extension study. Of 65 alcohol dependent adults initiating XR-NTX treatment, 40 (62%) completed the initial 12-week XR-NTX observational trial, and 19 (29%) continued treatment for a median of 38. weeks total (range, 16-72. weeks; median 8 total XR-NTX injections). Among active extension phase participants, self-reported rates of drinking days (vs. last 30 days pre-treatment baseline) were low: median 0.2 vs. 6.0. drinks per day; 82 vs. 38% days abstinent; 11 vs. 61% heavy drinking days. Long-term XR-NTX treatment in a primary care MM model was feasible and may promote lasting drinking reductions or alcohol abstinence (clinical trial: NCT00620750).

KW - Alcohol medical management

KW - Alcohol pharmacotherapy

KW - Alcohol treatment

KW - Extended-release naltrexone

KW - Primary care

UR - http://www.scopus.com/inward/record.url?scp=84868142386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868142386&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2012.08.012

DO - 10.1016/j.jsat.2012.08.012

M3 - Article

C2 - 22985676

AN - SCOPUS:84868142386

VL - 43

SP - 458

EP - 462

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 4

ER -